RxDoctor Payments Data

Blanka Kaplan, MD

Pediatric Allergy/Immunology · Great Neck, NYNPI 1184795270

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 34.7% of the total. That places this record below the midpoint for pediatric allergy/immunology clinicians in NY, where the typical reported total is $888.

$522in general payments, 2019–2025

Across 23 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$181
  • Takeda Pharmaceuticals U.S.A., Inc.$147
  • Genentech USA, Inc.$57
  • Shire North American Group Inc$34
  • Pharming Healthcare, Inc.$22
  • Sanofi$18
  • plus $63 from 4 others
$304,572in research payments, 2019–2025

Across 94 payments — averaging $3240.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$170K
  • Sanofi$52K
  • Regeneron$47K
  • Sanofi US Services Inc.$35K

What the payments were for

  • Food & beverage$50797%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$522 in reported general payments places this provider in the 40th percentile of 51 pediatric allergy/immunology providers in New York.

See all pediatric allergy/immunology providers in New York

Medicare billing

Part B allowed, 2024
$56,245
Medicare patients
131
Services billed
2,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5025$209,823
Dupixent PenDupilumab17$61,546
XolairOmalizumab13$39,764
Cromolyn Sodium16$3,384
Azelastine Hcl31$1,195
Levocetirizine Dihydrochloride13$251
Fluticasone Propionate18$228
Montelukast Sodium16$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$17$209,82325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 51 pediatric allergy/immunology providers in New York.

Other pediatric allergy/immunology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →